- Home
- INKT vs ENLV Comparison
INKT vs ENLV Comparison
Compare INKT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- ENLV
- Stock Information
- Founded
- INKT 2017
- ENLV 2005
- Country
- INKT United States
- ENLV Israel
- Employees
- INKT N/A
- ENLV N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- ENLV Health Care
- Exchange
- INKT Nasdaq
- ENLV Nasdaq
- Market Cap
- INKT 69.2M
- ENLV 25.5M
- IPO Year
- INKT 2021
- ENLV 1995
- Fundamental
- Price
- INKT $14.24
- ENLV $1.05
- Analyst Decision
- INKT Buy
- ENLV Strong Buy
- Analyst Count
- INKT 3
- ENLV 2
- Target Price
- INKT $37.50
- ENLV $10.00
- AVG Volume (30 Days)
- INKT 45.1K
- ENLV 355.7K
- Earning Date
- INKT 11-13-2025
- ENLV 08-29-2025
- Dividend Yield
- INKT N/A
- ENLV N/A
- EPS Growth
- INKT N/A
- ENLV N/A
- EPS
- INKT N/A
- ENLV N/A
- Revenue
- INKT N/A
- ENLV N/A
- Revenue This Year
- INKT N/A
- ENLV N/A
- Revenue Next Year
- INKT N/A
- ENLV N/A
- P/E Ratio
- INKT N/A
- ENLV N/A
- Revenue Growth
- INKT N/A
- ENLV N/A
- 52 Week Low
- INKT $4.56
- ENLV $0.81
- 52 Week High
- INKT $76.00
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- INKT 47.11
- ENLV 42.04
- Support Level
- INKT $13.11
- ENLV $1.00
- Resistance Level
- INKT $16.20
- ENLV $1.08
- Average True Range (ATR)
- INKT 1.13
- ENLV 0.04
- MACD
- INKT -0.01
- ENLV 0.01
- Stochastic Oscillator
- INKT 35.38
- ENLV 50.00
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.